Replies to post #209197 on Biotech Values

[DewDiligence]

SNY/AZN ink collaboration for MEDI8897—a successor to Synagis for prevention of RSV infection in infants:

http://finance.yahoo.com/news/sanofi-pasteur-medimmune-collaborate-monoclonal-070133318.html

Under the terms of the agreement, Sanofi Pasteur will make an upfront payment of €120 million and pay up to €495 million upon achievement of certain development and sales-related milestones. The two companies will share all costs and profits equally.

MedImmune will continue to lead all development activity up to the first approval, and AstraZeneca will retain MEDI8897 manufacturing activities. Sanofi-Pasteur will lead the commercialization activities for MEDI8897.

Note: This deal has no effect on ENTA’s RSV program, which seeks to develop a treatment for RSV infection in adults and children (#msg-119746650, #msg-128915696 [slides 23-26]).

[DewDiligence]

ENTA reports preclinical data on EDP-938 RSV inhibitor; phase-1 to begin 4Q17:

http://ir.enanta.com/news-releases/news-release-details/enanta-announces-new-data-edp-938-novel-non-fusion-inhibitor